Advanced Animal Diagnostics, Inc. commercializes proprietary technology for the diagnosis of farm-animal diseases. It uses an animal's own immune response to detect and stage infections to improve the quality of life for producers, processors, animals, and consumers. The company offers QuickSmear, a rapid differential slide to speed and simplify production animal research using differential cell counts; and SCC+ System for early detection of mastitis. Advanced Animal Diagnostics was founded in 2001 and is based in Durham, North Carolina.
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company that specializes in developing and commercializing innovative drug and delivery solutions for the localized treatment of ear, nose, and throat diseases. Utilizing its proprietary XTreo technology platform, the company aims to deliver medications directly to affected tissues for extended periods with a single administration. Its lead product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed for non-invasive in-office procedures, providing up to six months of continuous drug therapy specifically for chronic rhinosinusitis. The active ingredient in these formulations is mometasone furoate, which is recognized for its efficacy and safety in various FDA-approved therapies. Founded in 2005 and headquartered in Watertown, Massachusetts, Lyra Therapeutics was formerly known as 480 Biomedical, Inc. before rebranding in July 2018.
CSA Medical, Inc. develops and manufactures innovative spray cryotherapy medical devices aimed at the destruction of unwanted tissue in various medical fields, including dermatology, gynecology, and general surgery. The company's flagship product, the truFreeze spray cryotherapy device, utilizes cold liquid nitrogen as a cryosurgical tool, allowing for the targeted destruction of tissue while promoting the regeneration of healthy tissue. Additionally, CSA Medical offers the Rapid AV Spray Kit, which enhances the truFreeze system by reducing the time required for liquid nitrogen application. Founded in 1993 and originally known as Crymed Technologies, the company rebranded to CSA Medical in 2006 and is headquartered in Baltimore, Maryland, with a research and development facility located in Lexington, Massachusetts.
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company that specializes in developing and commercializing innovative drug and delivery solutions for the localized treatment of ear, nose, and throat diseases. Utilizing its proprietary XTreo technology platform, the company aims to deliver medications directly to affected tissues for extended periods with a single administration. Its lead product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed for non-invasive in-office procedures, providing up to six months of continuous drug therapy specifically for chronic rhinosinusitis. The active ingredient in these formulations is mometasone furoate, which is recognized for its efficacy and safety in various FDA-approved therapies. Founded in 2005 and headquartered in Watertown, Massachusetts, Lyra Therapeutics was formerly known as 480 Biomedical, Inc. before rebranding in July 2018.
Azalea Health is a prominent provider of cloud-based healthcare technologies and services, catering to health systems, rural health clinics, billing companies, and community hospitals. The company offers a comprehensive suite of integrated solutions, including Electronic Health Records (EHR), Practice Management (PM), Revenue Cycle Management (RCM), and telehealth services. Azalea Health focuses on enhancing patient engagement through its mobile health application and patient health records portal, which are designed to improve workflow and revenue flow for practices of various sizes and specialties. Additionally, the solutions offered by Azalea Health assist clients in meeting regulatory requirements, such as Meaningful Use and ICD-10 standards, thereby streamlining operations and maximizing revenue.
6fusion operates a cloud management platform that transforms public and private cloud resources into a pay-per-use utility model. Utilizing its proprietary Workload Allocation Cube, the company establishes a standardized method for measuring supply and demand of computing resources. This platform serves IT service providers, enterprises, independent software vendors, and infrastructure owners/operators by simplifying Infrastructure-as-a-Service management through a single console. It offers insights into consumption, performance benchmarking, and cost allocation, all while avoiding vendor lock-in. Additionally, 6fusion employs financial intelligence analytics to enhance the economic measurement of IT infrastructure operations, helping organizations analyze utilization rates, consumption patterns, and cost efficiencies effectively.
Locaid, a leading provider in the Location-as-a-Service (LaaS) sector, specializes in cloud-based geolocation services that enable businesses to determine the physical location of customers, employees, or assets almost instantly. With access to over 5 billion connected devices worldwide and mobile location capabilities on more than 360 million devices, Locaid supports enterprises and developers in enhancing productivity, reducing fraud, and gaining valuable consumer insights. The company serves as a key location gateway for major telecommunications carriers in the Americas, making it a preferred partner for numerous global brands, financial institutions, and technology firms. Locaid's Omni-Location™ platform prioritizes privacy and compliance, allowing organizations to leverage location data effectively while ensuring user consent. By providing advanced reporting, geofencing, and messaging services, Locaid equips businesses with the tools necessary to optimize operations and engage customers in a hyper-local context.
CallMiner, Inc. specializes in providing speech analytics solutions designed to enhance agent performance and improve contact center operations. The company offers a range of products, including the Eureka platform, which enables conversational analytics to uncover insights from interactions between agents and customers. It features tools such as myEureka for automated performance management, Eureka Live for real-time call monitoring, and Eureka Essentials for smaller contact centers. CallMiner's solutions are delivered through both Software-as-a-Service and on-premise installations, catering to various industries including financial services, utilities, manufacturing, and travel. Since its founding in 2002, CallMiner has established a significant presence in the market, with over 2 billion hours of conversations analyzed and a commitment to continuous improvement through customer feedback. The company also provides support services, training programs, and an online community for users. Headquartered in Waltham, Massachusetts, with additional offices in Fort Myers and the United Kingdom, CallMiner remains agile in adapting to the evolving needs of its clients.
480 Biomedical focuses on the development of a bioresorbable scaffold for treating occlusive disease in the superficial femoral artery (SFA). Its lead product, SFA scaffold, is a proprietary scaffold and delivery system for use in treating peripheral arterial disease in the SFA. The company was founded in 2011 and is based in Watertown, Massachusetts.
Arsenal Medical, Inc. is a platform technology company based in Watertown, Massachusetts, that specializes in developing polymer-based foams and fibers for the treatment of vascular diseases. Founded in 2005, the company focuses on creating in-situ forming foams to address acute hemorrhage and other critical medical conditions, including vascular injury and repair. Arsenal Medical's proprietary technologies include its therapeutic foam and AxioCore, a novel nanofiber technology designed to enhance cell integration and tissue regeneration, allowing for the controlled delivery of various biologics and therapeutics. The company is advancing multiple preclinical programs and is supported by venture funding as well as grants from prominent organizations, including the Department of Defense and the Bill & Melinda Gates Foundation.
Vascular Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of therapeutics for treating patients with type 1 and type 2 diabetes. It focuses on the development of VPI-2690B, a subcutaneously administered monoclonal antibody that is stimulated by hyperglycemia for the treatment of diabetic nephropathy. The company was founded in 2005 and is based in Research Triangle Park, North Carolina.
Azalea Health is a prominent provider of cloud-based healthcare technologies and services, catering to health systems, rural health clinics, billing companies, and community hospitals. The company offers a comprehensive suite of integrated solutions, including Electronic Health Records (EHR), Practice Management (PM), Revenue Cycle Management (RCM), and telehealth services. Azalea Health focuses on enhancing patient engagement through its mobile health application and patient health records portal, which are designed to improve workflow and revenue flow for practices of various sizes and specialties. Additionally, the solutions offered by Azalea Health assist clients in meeting regulatory requirements, such as Meaningful Use and ICD-10 standards, thereby streamlining operations and maximizing revenue.
Viamet Pharmaceuticals specializes in the discovery and development of novel therapeutic agents targeting metalloenzymes through its proprietary Metallophile™ Technology. This innovative approach leverages the company’s expertise in bioinorganic chemistry to develop inhibitors that demonstrate significant therapeutic and commercial potential. Viamet focuses on creating best-in-class analogs of existing metalloenzyme inhibitors, which allows for the rapid and cost-effective generation of patentable small molecule compounds. The company’s therapeutic pipeline addresses critical health challenges, including invasive fungal infections, cancer, cardiovascular conditions, and orphan diseases, by targeting the body's ability to utilize essential metal ions such as zinc and iron.
Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases.
The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics.
Proteon Therapeutics’ first drug candidate (PRT-201) is in development for the improvement of blood flow following vascular surgery procedures.
The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD).
CSA Medical, Inc. develops and manufactures innovative spray cryotherapy medical devices aimed at the destruction of unwanted tissue in various medical fields, including dermatology, gynecology, and general surgery. The company's flagship product, the truFreeze spray cryotherapy device, utilizes cold liquid nitrogen as a cryosurgical tool, allowing for the targeted destruction of tissue while promoting the regeneration of healthy tissue. Additionally, CSA Medical offers the Rapid AV Spray Kit, which enhances the truFreeze system by reducing the time required for liquid nitrogen application. Founded in 1993 and originally known as Crymed Technologies, the company rebranded to CSA Medical in 2006 and is headquartered in Baltimore, Maryland, with a research and development facility located in Lexington, Massachusetts.
Learn to play the music you love in the Zenph Online Education Network (ZOEN). We deliver the perfect match between teachers and students through live online music lessons. Whether you’re looking to learn your favorite song, seeking advice on perfecting your technique or searching for the right music teacher for your kids, taking a live online music lesson from one of the ZOEN’s experienced, nationally renowned music teachers is just a matter of a few clicks! The ZOEN is brought to you by Zenph, Inc. – our award winning Re-Performance® technology was named one of the “Best Ideas of the Year” by The New York Times Magazine and has earned us accolades from music lovers and critics the world over, including multiple GRAMMY® nominations. Based in North Carolina’s Research Triangle Park, we are a venture-backed technology company led by a team of music and software professionals with expertise in music education, consumer software, social gaming and entertainment.
Argos Therapeutics, Inc. was a biotechnology company based in Durham, North Carolina, focused on developing individualized immunotherapies for cancer, infectious diseases, and autoimmune disorders. Utilizing its proprietary Arcelis technology platform, the company aimed to create personalized treatments, including rocapuldencel-T, which was undergoing Phase III clinical trials for metastatic renal cell carcinoma, and AGS-004, in Phase II trials for human immunodeficiency virus. Argos also explored therapies for transplant rejection and autoimmune diseases, with products in various stages of development targeting conditions such as lupus and other inflammatory disorders. Founded in 1997, the company was previously known as Merix Bioscience, Inc. However, Argos Therapeutics ceased operations and filed for Chapter 7 bankruptcy on September 24, 2019.
PeopleMatter, Inc. is a workforce management platform that specializes in talent management software designed to enhance the performance of service-industry brands. Founded in 2001 and based in Charleston, South Carolina, the company provides solutions tailored for various sectors, including technology, transportation, healthcare, government, biotech, and recreation. PeopleMatter offers a comprehensive hire-to-retire system that simplifies the hiring process for hourly and shift workers, enabling managers to source, screen, and onboard employees more efficiently. By streamlining applicant tracking and onboarding, the platform aims to reduce friction in recruiting and improve overall efficiency, engagement, and customer satisfaction within the service industry. In June 2016, PeopleMatter was acquired by Snagajob.
Argos Therapeutics, Inc. was a biotechnology company based in Durham, North Carolina, focused on developing individualized immunotherapies for cancer, infectious diseases, and autoimmune disorders. Utilizing its proprietary Arcelis technology platform, the company aimed to create personalized treatments, including rocapuldencel-T, which was undergoing Phase III clinical trials for metastatic renal cell carcinoma, and AGS-004, in Phase II trials for human immunodeficiency virus. Argos also explored therapies for transplant rejection and autoimmune diseases, with products in various stages of development targeting conditions such as lupus and other inflammatory disorders. Founded in 1997, the company was previously known as Merix Bioscience, Inc. However, Argos Therapeutics ceased operations and filed for Chapter 7 bankruptcy on September 24, 2019.
Locaid, a leading provider in the Location-as-a-Service (LaaS) sector, specializes in cloud-based geolocation services that enable businesses to determine the physical location of customers, employees, or assets almost instantly. With access to over 5 billion connected devices worldwide and mobile location capabilities on more than 360 million devices, Locaid supports enterprises and developers in enhancing productivity, reducing fraud, and gaining valuable consumer insights. The company serves as a key location gateway for major telecommunications carriers in the Americas, making it a preferred partner for numerous global brands, financial institutions, and technology firms. Locaid's Omni-Location™ platform prioritizes privacy and compliance, allowing organizations to leverage location data effectively while ensuring user consent. By providing advanced reporting, geofencing, and messaging services, Locaid equips businesses with the tools necessary to optimize operations and engage customers in a hyper-local context.
Advanced Animal Diagnostics, Inc. commercializes proprietary technology for the diagnosis of farm-animal diseases. It uses an animal's own immune response to detect and stage infections to improve the quality of life for producers, processors, animals, and consumers. The company offers QuickSmear, a rapid differential slide to speed and simplify production animal research using differential cell counts; and SCC+ System for early detection of mastitis. Advanced Animal Diagnostics was founded in 2001 and is based in Durham, North Carolina.
PeopleMatter, Inc. is a workforce management platform that specializes in talent management software designed to enhance the performance of service-industry brands. Founded in 2001 and based in Charleston, South Carolina, the company provides solutions tailored for various sectors, including technology, transportation, healthcare, government, biotech, and recreation. PeopleMatter offers a comprehensive hire-to-retire system that simplifies the hiring process for hourly and shift workers, enabling managers to source, screen, and onboard employees more efficiently. By streamlining applicant tracking and onboarding, the platform aims to reduce friction in recruiting and improve overall efficiency, engagement, and customer satisfaction within the service industry. In June 2016, PeopleMatter was acquired by Snagajob.
Applied Genetic Technologies Corporation is a clinical-stage biotechnology company focused on developing innovative genetic therapies for patients with rare and debilitating diseases. The company is advancing several product candidates in ophthalmology, including treatments for X-linked retinitis pigmentosa, which has completed Phase I/II clinical trials, and achromatopsia, currently in Phase I/II trials. Additionally, AGTC is working on an optogenetic therapy for patients with advanced retinal disease. The company has also initiated a preclinical program in otology and three preclinical programs targeting central nervous system disorders such as frontotemporal dementia, amyotrophic lateral sclerosis, and adrenoleukodystrophy. Collaborations with various organizations, including Synpromics Limited and the University of Florida, support its research efforts. Founded in 1999 and based in Alachua, Florida, AGTC employs advanced gene therapy techniques, aiming to replace defective genes with functional ones, thus improving patient outcomes with long-lasting treatments.
Zenoss Inc. develops IT operations and application monitoring solutions, focusing on ensuring the reliability of IT services for large organizations. The company's flagship product, Zenoss Cloud, is a software-as-a-service platform that normalizes machine data to help prevent service disruptions in complex IT environments. Additionally, Zenoss offers VxRail HCI integration, allowing users to monitor entire VxRail deployments as cohesive units. Their solutions cater to various domains, including IT services, virtualization, and network monitoring, and are utilized by industries such as federal, financial, and technology sectors, as well as service providers. Zenoss has established strategic partnerships with notable companies like Accenture and AWS, enhancing its service offerings. Founded in 2005 and headquartered in Austin, Texas, with an office in Coventry, United Kingdom, Zenoss continues to lead in software-defined IT operations by leveraging machine learning to predict and mitigate potential outages, thus reducing downtime and associated costs.
ABT Molecular Imaging, based in Knoxville, Tennessee, specializes in medical imaging by designing, manufacturing, and marketing biomarker generator systems and related accessories. The company’s flagship product, the BG-75 Biomarker Generator, produces unit doses of molecular imaging drugs for positron emission tomography (PET) at the point of use, allowing for on-demand generation of PET biomarkers and radioisotopes. This innovative platform incorporates quality control tests and maintains dose records for each generated dose, ensuring high standards in medical imaging. Founded in 2006 by industry experts Ron and Lynda Nutt, ABT Molecular Imaging distributes its products through a global network of sales and service partners.
Vascular Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of therapeutics for treating patients with type 1 and type 2 diabetes. It focuses on the development of VPI-2690B, a subcutaneously administered monoclonal antibody that is stimulated by hyperglycemia for the treatment of diabetic nephropathy. The company was founded in 2005 and is based in Research Triangle Park, North Carolina.
Private Equity Round in 2012
Locaid, a leading provider in the Location-as-a-Service (LaaS) sector, specializes in cloud-based geolocation services that enable businesses to determine the physical location of customers, employees, or assets almost instantly. With access to over 5 billion connected devices worldwide and mobile location capabilities on more than 360 million devices, Locaid supports enterprises and developers in enhancing productivity, reducing fraud, and gaining valuable consumer insights. The company serves as a key location gateway for major telecommunications carriers in the Americas, making it a preferred partner for numerous global brands, financial institutions, and technology firms. Locaid's Omni-Location™ platform prioritizes privacy and compliance, allowing organizations to leverage location data effectively while ensuring user consent. By providing advanced reporting, geofencing, and messaging services, Locaid equips businesses with the tools necessary to optimize operations and engage customers in a hyper-local context.
Esanex
Venture Round in 2012
Esanex is a drug development company focused on advancing its highly selective, orally active Hsp90 inhibitors. SNX-5422, created from a novel chemical scaffold that is unique in the Hsp90 field, has shown outstanding pre-clinical activity in a number of tumor models and is currently completing Phase 1 trials.
Argos Therapeutics, Inc. was a biotechnology company based in Durham, North Carolina, focused on developing individualized immunotherapies for cancer, infectious diseases, and autoimmune disorders. Utilizing its proprietary Arcelis technology platform, the company aimed to create personalized treatments, including rocapuldencel-T, which was undergoing Phase III clinical trials for metastatic renal cell carcinoma, and AGS-004, in Phase II trials for human immunodeficiency virus. Argos also explored therapies for transplant rejection and autoimmune diseases, with products in various stages of development targeting conditions such as lupus and other inflammatory disorders. Founded in 1997, the company was previously known as Merix Bioscience, Inc. However, Argos Therapeutics ceased operations and filed for Chapter 7 bankruptcy on September 24, 2019.
Advanced Animal Diagnostics, Inc. commercializes proprietary technology for the diagnosis of farm-animal diseases. It uses an animal's own immune response to detect and stage infections to improve the quality of life for producers, processors, animals, and consumers. The company offers QuickSmear, a rapid differential slide to speed and simplify production animal research using differential cell counts; and SCC+ System for early detection of mastitis. Advanced Animal Diagnostics was founded in 2001 and is based in Durham, North Carolina.
Adaptivity is the IT Blueprint Company. Founded in late 2007 by veteran IT practitioners who have dedicated their careers to changing the way IT is delivered. Our efforts have resulted in numerous industry awards for leveraging real time infrastructure, virtual datacenters and cloud utility models to deliver business impact. Adaptivity was created to address the design challenges facing enterprise IT. We are leveraging our proven experience, industry partnerships and lessons learned to create a codified intelligent design platform to enable enterprise IT to optimize, re-design and create new systems in a dynamical, virtual and agile manner.
Semprius, Inc. is focused on the design, development, and manufacture of high concentration photovoltaic (HCPV) solar modules aimed at generating solar energy for utility, commercial, and government applications in sunny and arid regions globally. The company utilizes a proprietary micro-transfer printing technology that enhances the performance and reliability of its solar modules while ensuring low production costs and scalability for high-volume output. In addition to its solar offerings, Semprius licenses its micro-transfer printing technology for various non-solar applications, including flat-panel displays, flexible electronics, and large-area sensors, which require lightweight and thin form factors. Founded in 2005 and headquartered in Durham, North Carolina, Semprius aims to make solar power generation more economically viable and supports diverse technology applications through its innovative solutions.
CSA Medical, Inc. develops and manufactures innovative spray cryotherapy medical devices aimed at the destruction of unwanted tissue in various medical fields, including dermatology, gynecology, and general surgery. The company's flagship product, the truFreeze spray cryotherapy device, utilizes cold liquid nitrogen as a cryosurgical tool, allowing for the targeted destruction of tissue while promoting the regeneration of healthy tissue. Additionally, CSA Medical offers the Rapid AV Spray Kit, which enhances the truFreeze system by reducing the time required for liquid nitrogen application. Founded in 1993 and originally known as Crymed Technologies, the company rebranded to CSA Medical in 2006 and is headquartered in Baltimore, Maryland, with a research and development facility located in Lexington, Massachusetts.
simplifyMD, based in Alpharetta, Georgia, is an electronic health records (EHR) provider established in 2006. The company offers a web-based platform designed for physician practices, featuring ONC-ATCB certified technologies that enhance the management of electronic medical records. simplifyMD's solutions include medical-grade document management and Patient Health Record technologies, utilizing barcode and optical character recognition to streamline the handling of documents. This innovative approach allows healthcare offices to automatically index and manage their records, reducing the need for manual sorting of scans and improving overall efficiency in medical record management.
480 Biomedical focuses on the development of a bioresorbable scaffold for treating occlusive disease in the superficial femoral artery (SFA). Its lead product, SFA scaffold, is a proprietary scaffold and delivery system for use in treating peripheral arterial disease in the SFA. The company was founded in 2011 and is based in Watertown, Massachusetts.
Adaptivity is the IT Blueprint Company. Founded in late 2007 by veteran IT practitioners who have dedicated their careers to changing the way IT is delivered. Our efforts have resulted in numerous industry awards for leveraging real time infrastructure, virtual datacenters and cloud utility models to deliver business impact. Adaptivity was created to address the design challenges facing enterprise IT. We are leveraging our proven experience, industry partnerships and lessons learned to create a codified intelligent design platform to enable enterprise IT to optimize, re-design and create new systems in a dynamical, virtual and agile manner.
Arsenal Medical, Inc. is a platform technology company based in Watertown, Massachusetts, that specializes in developing polymer-based foams and fibers for the treatment of vascular diseases. Founded in 2005, the company focuses on creating in-situ forming foams to address acute hemorrhage and other critical medical conditions, including vascular injury and repair. Arsenal Medical's proprietary technologies include its therapeutic foam and AxioCore, a novel nanofiber technology designed to enhance cell integration and tissue regeneration, allowing for the controlled delivery of various biologics and therapeutics. The company is advancing multiple preclinical programs and is supported by venture funding as well as grants from prominent organizations, including the Department of Defense and the Bill & Melinda Gates Foundation.
6fusion operates a cloud management platform that transforms public and private cloud resources into a pay-per-use utility model. Utilizing its proprietary Workload Allocation Cube, the company establishes a standardized method for measuring supply and demand of computing resources. This platform serves IT service providers, enterprises, independent software vendors, and infrastructure owners/operators by simplifying Infrastructure-as-a-Service management through a single console. It offers insights into consumption, performance benchmarking, and cost allocation, all while avoiding vendor lock-in. Additionally, 6fusion employs financial intelligence analytics to enhance the economic measurement of IT infrastructure operations, helping organizations analyze utilization rates, consumption patterns, and cost efficiencies effectively.
Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases.
The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics.
Proteon Therapeutics’ first drug candidate (PRT-201) is in development for the improvement of blood flow following vascular surgery procedures.
The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD).
Semprius, Inc. is focused on the design, development, and manufacture of high concentration photovoltaic (HCPV) solar modules aimed at generating solar energy for utility, commercial, and government applications in sunny and arid regions globally. The company utilizes a proprietary micro-transfer printing technology that enhances the performance and reliability of its solar modules while ensuring low production costs and scalability for high-volume output. In addition to its solar offerings, Semprius licenses its micro-transfer printing technology for various non-solar applications, including flat-panel displays, flexible electronics, and large-area sensors, which require lightweight and thin form factors. Founded in 2005 and headquartered in Durham, North Carolina, Semprius aims to make solar power generation more economically viable and supports diverse technology applications through its innovative solutions.
PeopleMatter, Inc. is a workforce management platform that specializes in talent management software designed to enhance the performance of service-industry brands. Founded in 2001 and based in Charleston, South Carolina, the company provides solutions tailored for various sectors, including technology, transportation, healthcare, government, biotech, and recreation. PeopleMatter offers a comprehensive hire-to-retire system that simplifies the hiring process for hourly and shift workers, enabling managers to source, screen, and onboard employees more efficiently. By streamlining applicant tracking and onboarding, the platform aims to reduce friction in recruiting and improve overall efficiency, engagement, and customer satisfaction within the service industry. In June 2016, PeopleMatter was acquired by Snagajob.
Advanced Animal Diagnostics, Inc. commercializes proprietary technology for the diagnosis of farm-animal diseases. It uses an animal's own immune response to detect and stage infections to improve the quality of life for producers, processors, animals, and consumers. The company offers QuickSmear, a rapid differential slide to speed and simplify production animal research using differential cell counts; and SCC+ System for early detection of mastitis. Advanced Animal Diagnostics was founded in 2001 and is based in Durham, North Carolina.
Locaid, a leading provider in the Location-as-a-Service (LaaS) sector, specializes in cloud-based geolocation services that enable businesses to determine the physical location of customers, employees, or assets almost instantly. With access to over 5 billion connected devices worldwide and mobile location capabilities on more than 360 million devices, Locaid supports enterprises and developers in enhancing productivity, reducing fraud, and gaining valuable consumer insights. The company serves as a key location gateway for major telecommunications carriers in the Americas, making it a preferred partner for numerous global brands, financial institutions, and technology firms. Locaid's Omni-Location™ platform prioritizes privacy and compliance, allowing organizations to leverage location data effectively while ensuring user consent. By providing advanced reporting, geofencing, and messaging services, Locaid equips businesses with the tools necessary to optimize operations and engage customers in a hyper-local context.
CallMiner, Inc. specializes in providing speech analytics solutions designed to enhance agent performance and improve contact center operations. The company offers a range of products, including the Eureka platform, which enables conversational analytics to uncover insights from interactions between agents and customers. It features tools such as myEureka for automated performance management, Eureka Live for real-time call monitoring, and Eureka Essentials for smaller contact centers. CallMiner's solutions are delivered through both Software-as-a-Service and on-premise installations, catering to various industries including financial services, utilities, manufacturing, and travel. Since its founding in 2002, CallMiner has established a significant presence in the market, with over 2 billion hours of conversations analyzed and a commitment to continuous improvement through customer feedback. The company also provides support services, training programs, and an online community for users. Headquartered in Waltham, Massachusetts, with additional offices in Fort Myers and the United Kingdom, CallMiner remains agile in adapting to the evolving needs of its clients.
Adaptivity is the IT Blueprint Company. Founded in late 2007 by veteran IT practitioners who have dedicated their careers to changing the way IT is delivered. Our efforts have resulted in numerous industry awards for leveraging real time infrastructure, virtual datacenters and cloud utility models to deliver business impact. Adaptivity was created to address the design challenges facing enterprise IT. We are leveraging our proven experience, industry partnerships and lessons learned to create a codified intelligent design platform to enable enterprise IT to optimize, re-design and create new systems in a dynamical, virtual and agile manner.
CallMiner, Inc. specializes in providing speech analytics solutions designed to enhance agent performance and improve contact center operations. The company offers a range of products, including the Eureka platform, which enables conversational analytics to uncover insights from interactions between agents and customers. It features tools such as myEureka for automated performance management, Eureka Live for real-time call monitoring, and Eureka Essentials for smaller contact centers. CallMiner's solutions are delivered through both Software-as-a-Service and on-premise installations, catering to various industries including financial services, utilities, manufacturing, and travel. Since its founding in 2002, CallMiner has established a significant presence in the market, with over 2 billion hours of conversations analyzed and a commitment to continuous improvement through customer feedback. The company also provides support services, training programs, and an online community for users. Headquartered in Waltham, Massachusetts, with additional offices in Fort Myers and the United Kingdom, CallMiner remains agile in adapting to the evolving needs of its clients.
6fusion operates a cloud management platform that transforms public and private cloud resources into a pay-per-use utility model. Utilizing its proprietary Workload Allocation Cube, the company establishes a standardized method for measuring supply and demand of computing resources. This platform serves IT service providers, enterprises, independent software vendors, and infrastructure owners/operators by simplifying Infrastructure-as-a-Service management through a single console. It offers insights into consumption, performance benchmarking, and cost allocation, all while avoiding vendor lock-in. Additionally, 6fusion employs financial intelligence analytics to enhance the economic measurement of IT infrastructure operations, helping organizations analyze utilization rates, consumption patterns, and cost efficiencies effectively.
Arsenal Medical, Inc. is a platform technology company based in Watertown, Massachusetts, that specializes in developing polymer-based foams and fibers for the treatment of vascular diseases. Founded in 2005, the company focuses on creating in-situ forming foams to address acute hemorrhage and other critical medical conditions, including vascular injury and repair. Arsenal Medical's proprietary technologies include its therapeutic foam and AxioCore, a novel nanofiber technology designed to enhance cell integration and tissue regeneration, allowing for the controlled delivery of various biologics and therapeutics. The company is advancing multiple preclinical programs and is supported by venture funding as well as grants from prominent organizations, including the Department of Defense and the Bill & Melinda Gates Foundation.
Overture Networks, Inc. specializes in providing virtualization solutions and high-speed carrier Ethernet services to service providers. The company offers a range of products designed to facilitate cost-effective service delivery and revenue generation. Key offerings include the Overture Orchestrator for operational efficiency, Overture Analytics for actionable intelligence, and an open-source SDN controller to manage network configurations. Its hardware solutions, such as the Overture 65, Overture 1400, and Overture 6500, cater to various needs, from Ethernet access devices to carrier-grade aggregation and switching platforms. These products enable seamless integration of packet-switched and circuit-switched technologies, facilitating service delivery over copper, fiber, or optical transport. Founded in 2000 and headquartered in Morrisville, North Carolina, Overture Networks also has development offices in Westford, Massachusetts, and Bangalore, India. The company operates as a subsidiary of ADVA Optical Networking SE.
PeopleMatter, Inc. is a workforce management platform that specializes in talent management software designed to enhance the performance of service-industry brands. Founded in 2001 and based in Charleston, South Carolina, the company provides solutions tailored for various sectors, including technology, transportation, healthcare, government, biotech, and recreation. PeopleMatter offers a comprehensive hire-to-retire system that simplifies the hiring process for hourly and shift workers, enabling managers to source, screen, and onboard employees more efficiently. By streamlining applicant tracking and onboarding, the platform aims to reduce friction in recruiting and improve overall efficiency, engagement, and customer satisfaction within the service industry. In June 2016, PeopleMatter was acquired by Snagajob.
ABT Molecular Imaging, based in Knoxville, Tennessee, specializes in medical imaging by designing, manufacturing, and marketing biomarker generator systems and related accessories. The company’s flagship product, the BG-75 Biomarker Generator, produces unit doses of molecular imaging drugs for positron emission tomography (PET) at the point of use, allowing for on-demand generation of PET biomarkers and radioisotopes. This innovative platform incorporates quality control tests and maintains dose records for each generated dose, ensuring high standards in medical imaging. Founded in 2006 by industry experts Ron and Lynda Nutt, ABT Molecular Imaging distributes its products through a global network of sales and service partners.
MicroCHIPS Biotech, Inc. specializes in developing a microchip-based implant designed for drug delivery applications across various therapeutic areas, including osteoporosis, diabetes, multiple sclerosis, women’s contraception, and pain management. This innovative implant can store and release precise doses of medication over extended periods, offering an alternative to traditional therapies that rely on frequent injections. The implant is surgically placed under the skin during a minimally invasive procedure and can be wirelessly activated or deactivated by healthcare providers or patients. Additionally, the device allows for real-time adjustments to the drug dosage and frequency, catering to the specific needs of each patient. Established in 1999 and headquartered in Lexington, Massachusetts, MicroCHIPS operates as a subsidiary of Daré Bioscience, Inc.
PeopleMatter, Inc. is a workforce management platform that specializes in talent management software designed to enhance the performance of service-industry brands. Founded in 2001 and based in Charleston, South Carolina, the company provides solutions tailored for various sectors, including technology, transportation, healthcare, government, biotech, and recreation. PeopleMatter offers a comprehensive hire-to-retire system that simplifies the hiring process for hourly and shift workers, enabling managers to source, screen, and onboard employees more efficiently. By streamlining applicant tracking and onboarding, the platform aims to reduce friction in recruiting and improve overall efficiency, engagement, and customer satisfaction within the service industry. In June 2016, PeopleMatter was acquired by Snagajob.
Calibra Medical
Venture Round in 2009
Calibra Medical, Inc. develops medical devices and technologies in the diabetes sector. It offers insulin delivery devices. The company was formerly known as Seattle Medical Technologies, Inc. Calibra Medical, Inc. was founded in 2004 and is based in Redwood City, California.
Zenph Sound Innovations
Series A in 2009
Acquired by Steinway & Sons Inc., January 2015. Zenph Sound Innovations is a developer of musical analysis technology focused on software services and apps related to music. Zenph Sound Innovations offers technology that converts audio recordings into datasets, enabling a virtual artist play re-performances, precisely replicating a musician’s playing in an original recording.
TransEnterix, Inc. is a medical device company that focuses on the research, development, and sale of robotic systems designed to enhance minimally invasive surgery. Its primary products include the Senhance System, a multi-port robotic surgery system that utilizes multiple robotic arms for instrument control and camera operation, and the SurgiBot System, a single-port robotically enhanced laparoscopic surgical platform. These systems enable surgeons to perform complex procedures, such as gallbladder removal, with minimal scarring. TransEnterix markets its products directly and through distributors in various regions, including Europe, the United States, Japan, and Taiwan. Founded in 2006, the company is headquartered in Morrisville, North Carolina.
Alimera Sciences is a pharmaceutical company that specializes in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. They are presently focused on diseases affecting the back of the eye, or retina because these diseases are not well treated with current therapies and will affect millions of people in their aging populations.
It was founded in 2003 and is headquartered in Alpharetta, Georgia.
Viamet Pharmaceuticals specializes in the discovery and development of novel therapeutic agents targeting metalloenzymes through its proprietary Metallophile™ Technology. This innovative approach leverages the company’s expertise in bioinorganic chemistry to develop inhibitors that demonstrate significant therapeutic and commercial potential. Viamet focuses on creating best-in-class analogs of existing metalloenzyme inhibitors, which allows for the rapid and cost-effective generation of patentable small molecule compounds. The company’s therapeutic pipeline addresses critical health challenges, including invasive fungal infections, cancer, cardiovascular conditions, and orphan diseases, by targeting the body's ability to utilize essential metal ions such as zinc and iron.
Semprius, Inc. is focused on the design, development, and manufacture of high concentration photovoltaic (HCPV) solar modules aimed at generating solar energy for utility, commercial, and government applications in sunny and arid regions globally. The company utilizes a proprietary micro-transfer printing technology that enhances the performance and reliability of its solar modules while ensuring low production costs and scalability for high-volume output. In addition to its solar offerings, Semprius licenses its micro-transfer printing technology for various non-solar applications, including flat-panel displays, flexible electronics, and large-area sensors, which require lightweight and thin form factors. Founded in 2005 and headquartered in Durham, North Carolina, Semprius aims to make solar power generation more economically viable and supports diverse technology applications through its innovative solutions.
Applied Genetic Technologies Corporation is a clinical-stage biotechnology company focused on developing innovative genetic therapies for patients with rare and debilitating diseases. The company is advancing several product candidates in ophthalmology, including treatments for X-linked retinitis pigmentosa, which has completed Phase I/II clinical trials, and achromatopsia, currently in Phase I/II trials. Additionally, AGTC is working on an optogenetic therapy for patients with advanced retinal disease. The company has also initiated a preclinical program in otology and three preclinical programs targeting central nervous system disorders such as frontotemporal dementia, amyotrophic lateral sclerosis, and adrenoleukodystrophy. Collaborations with various organizations, including Synpromics Limited and the University of Florida, support its research efforts. Founded in 1999 and based in Alachua, Florida, AGTC employs advanced gene therapy techniques, aiming to replace defective genes with functional ones, thus improving patient outcomes with long-lasting treatments.
Cempra is a clinical-stage pharmaceutical company dedicated to discovering and developing innovative medicines aimed at curing bacterial infections and enhancing the quality of life for individuals with chronic illnesses. The company focuses on creating antibiotics specifically designed to treat multi-drug resistant bacterial infections, offering advanced treatment options for patients both in hospitals and within the community. Cempra is currently advancing the development of its lead product, CEM-101, while simultaneously investing in new technologies to discover the next generation of antibiotics. Through this dual approach, Cempra aims to address the growing challenge of drug resistance in bacterial infections.
Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases.
The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics.
Proteon Therapeutics’ first drug candidate (PRT-201) is in development for the improvement of blood flow following vascular surgery procedures.
The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD).
Bright View Technologies, Inc. specializes in the development of microstructure-based optical films tailored for the global display industry. The company employs patented technologies to create advanced optical film products that enhance performance in various display types, including Plasma, LCD, Rear Projection, Front Projection, and OLED. Additionally, Bright View's engineered optics devices are applicable in other areas such as lighting and LiDAR, allowing clients to achieve improved brightness, efficiency, and uniformity in their display applications. Through its innovative approach, Bright View Technologies aims to meet the evolving needs of the display market.
Ziptronix, Inc. specializes in semiconductor integration technologies for the electronics industry. The company is known for its advanced chip stacking and three-dimensional integrated circuits, which enhance the density of signal paths through innovative bonding techniques. Its proprietary ZiBond and Direct Bond Interconnect technologies enable the bonding of silicon in a 3D configuration, optimizing performance and efficiency. Additionally, Ziptronix provides semiconductor substrates for microelectromechanical systems (MEMS) and radio-frequency (RF) devices, further expanding its offerings in the semiconductor market.
Biolex Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutic proteins and monoclonal antibodies using its patented LEX System. This innovative technology genetically transforms the aquatic plant Lemna to facilitate the production of biologic product candidates that are challenging to manufacture. Biolex's primary product is designed to address the needs of patients afflicted with Hepatitis C, aiming to improve treatment outcomes through enhanced efficacy and potency of its therapeutic offerings.
Clarabridge is a prominent Customer Experience Management platform that assists leading brands in enhancing their customer experience. The company employs advanced text analytics and enterprise survey tools to analyze various forms of customer feedback. By transforming this feedback into actionable insights, Clarabridge enables businesses to make informed decisions that improve customer satisfaction and engagement. Through its robust solutions, the company empowers organizations to understand their customers better and take decisive actions to elevate their overall experience.
Calibra Medical
Series B in 2008
Calibra Medical, Inc. develops medical devices and technologies in the diabetes sector. It offers insulin delivery devices. The company was formerly known as Seattle Medical Technologies, Inc. Calibra Medical, Inc. was founded in 2004 and is based in Redwood City, California.
Athenix is a leader in agricultural and industrial biotechnology. They have built the infrastructure necessary to discover new genes and to develop them into products that meet real customer needs.
siXis is a semiconductor company.
Argos Therapeutics, Inc. was a biotechnology company based in Durham, North Carolina, focused on developing individualized immunotherapies for cancer, infectious diseases, and autoimmune disorders. Utilizing its proprietary Arcelis technology platform, the company aimed to create personalized treatments, including rocapuldencel-T, which was undergoing Phase III clinical trials for metastatic renal cell carcinoma, and AGS-004, in Phase II trials for human immunodeficiency virus. Argos also explored therapies for transplant rejection and autoimmune diseases, with products in various stages of development targeting conditions such as lupus and other inflammatory disorders. Founded in 1997, the company was previously known as Merix Bioscience, Inc. However, Argos Therapeutics ceased operations and filed for Chapter 7 bankruptcy on September 24, 2019.
ALDAGEN is a biopharmaceutical company developing proprietary regenerative cell therapies that target significant unmet medical needs. We have four product candidates in clinical trials. Our most advanced product candidate is ALD-101. We are currently conducting a pivotal Phase 3 clinical trial of ALD-101 to evaluate its efficacy in improving umbilical cord blood, or cord blood, transplants used to treat inherited metabolic diseases in pediatric patients. We are also conducting or supporting Phase 1 or Phase 1/2 clinical trials of three other product candidates ALD--151 to improve cord blood transplants used for the treatment of leukemia; ALD-301 to treat critical limb ischemia; and ALD-201 to treat ischemic heart failure.
Alimera Sciences is a pharmaceutical company that specializes in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. They are presently focused on diseases affecting the back of the eye, or retina because these diseases are not well treated with current therapies and will affect millions of people in their aging populations.
It was founded in 2003 and is headquartered in Alpharetta, Georgia.
Ziptronix, Inc. specializes in semiconductor integration technologies for the electronics industry. The company is known for its advanced chip stacking and three-dimensional integrated circuits, which enhance the density of signal paths through innovative bonding techniques. Its proprietary ZiBond and Direct Bond Interconnect technologies enable the bonding of silicon in a 3D configuration, optimizing performance and efficiency. Additionally, Ziptronix provides semiconductor substrates for microelectromechanical systems (MEMS) and radio-frequency (RF) devices, further expanding its offerings in the semiconductor market.
Mixx is a user-driven social media platform that enables individuals to discover, share, and engage with content tailored to their interests and geographical location. Founded by Chris McGill, the platform combines elements of social networking with news sharing, allowing users to create a personalized experience similar to Digg, but focused on niche topics often overlooked by larger sites. Users can submit, edit, and vote on stories, photos, and videos, contributing to a dynamic community. Mixx also facilitates the creation of topic-based groups, further refining the news feed for participants. By partnering with niche publishers, Mixx aims to drive traffic between its platform and their content, providing a space for less mainstream stories to gain visibility. Since its inception, Mixx has continued to evolve, offering tools and applications that enhance user interaction and engagement within its social news ecosystem.
Zenoss Inc. develops IT operations and application monitoring solutions, focusing on ensuring the reliability of IT services for large organizations. The company's flagship product, Zenoss Cloud, is a software-as-a-service platform that normalizes machine data to help prevent service disruptions in complex IT environments. Additionally, Zenoss offers VxRail HCI integration, allowing users to monitor entire VxRail deployments as cohesive units. Their solutions cater to various domains, including IT services, virtualization, and network monitoring, and are utilized by industries such as federal, financial, and technology sectors, as well as service providers. Zenoss has established strategic partnerships with notable companies like Accenture and AWS, enhancing its service offerings. Founded in 2005 and headquartered in Austin, Texas, with an office in Coventry, United Kingdom, Zenoss continues to lead in software-defined IT operations by leveraging machine learning to predict and mitigate potential outages, thus reducing downtime and associated costs.
NovaMin Technology provides a range of oral hygiene solutions. The company was founded by Randy Scott in 2004 and is based in Alachua, Florida.
nContact, Inc. is a medical device company specializing in the development of innovative solutions for the treatment of cardiac arrhythmias, particularly atrial fibrillation. Founded in 2005 and based in Morrisville, North Carolina, the company focuses on minimally invasive ablation procedures. Its flagship product, the Numeris Coagulation System with VisiTrax, utilizes a unique combination of suction, perfusion, and radiofrequency energy to create visible, nonconductive lesions on the epicardium of a beating heart. This system has received regulatory approval for use in the United States and holds CE Mark approval in Europe. nContact also offers a range of other devices designed to ensure consistent contact with cardiac tissue, facilitating effective lesion creation. The company has initiated clinical studies to further explore its technology's application in treating atrial fibrillation through both open and closed chest procedures. In 2011, nContact, formerly known as nContact Surgical, became a subsidiary of AtriCure, Inc.
Arsenal Medical, Inc. is a platform technology company based in Watertown, Massachusetts, that specializes in developing polymer-based foams and fibers for the treatment of vascular diseases. Founded in 2005, the company focuses on creating in-situ forming foams to address acute hemorrhage and other critical medical conditions, including vascular injury and repair. Arsenal Medical's proprietary technologies include its therapeutic foam and AxioCore, a novel nanofiber technology designed to enhance cell integration and tissue regeneration, allowing for the controlled delivery of various biologics and therapeutics. The company is advancing multiple preclinical programs and is supported by venture funding as well as grants from prominent organizations, including the Department of Defense and the Bill & Melinda Gates Foundation.
Overture Networks, Inc. specializes in providing virtualization solutions and high-speed carrier Ethernet services to service providers. The company offers a range of products designed to facilitate cost-effective service delivery and revenue generation. Key offerings include the Overture Orchestrator for operational efficiency, Overture Analytics for actionable intelligence, and an open-source SDN controller to manage network configurations. Its hardware solutions, such as the Overture 65, Overture 1400, and Overture 6500, cater to various needs, from Ethernet access devices to carrier-grade aggregation and switching platforms. These products enable seamless integration of packet-switched and circuit-switched technologies, facilitating service delivery over copper, fiber, or optical transport. Founded in 2000 and headquartered in Morrisville, North Carolina, Overture Networks also has development offices in Westford, Massachusetts, and Bangalore, India. The company operates as a subsidiary of ADVA Optical Networking SE.
Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases.
The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics.
Proteon Therapeutics’ first drug candidate (PRT-201) is in development for the improvement of blood flow following vascular surgery procedures.
The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD).
ALDAGEN is a biopharmaceutical company developing proprietary regenerative cell therapies that target significant unmet medical needs. We have four product candidates in clinical trials. Our most advanced product candidate is ALD-101. We are currently conducting a pivotal Phase 3 clinical trial of ALD-101 to evaluate its efficacy in improving umbilical cord blood, or cord blood, transplants used to treat inherited metabolic diseases in pediatric patients. We are also conducting or supporting Phase 1 or Phase 1/2 clinical trials of three other product candidates ALD--151 to improve cord blood transplants used for the treatment of leukemia; ALD-301 to treat critical limb ischemia; and ALD-201 to treat ischemic heart failure.
Semprius, Inc. is focused on the design, development, and manufacture of high concentration photovoltaic (HCPV) solar modules aimed at generating solar energy for utility, commercial, and government applications in sunny and arid regions globally. The company utilizes a proprietary micro-transfer printing technology that enhances the performance and reliability of its solar modules while ensuring low production costs and scalability for high-volume output. In addition to its solar offerings, Semprius licenses its micro-transfer printing technology for various non-solar applications, including flat-panel displays, flexible electronics, and large-area sensors, which require lightweight and thin form factors. Founded in 2005 and headquartered in Durham, North Carolina, Semprius aims to make solar power generation more economically viable and supports diverse technology applications through its innovative solutions.
Cempra is a clinical-stage pharmaceutical company dedicated to discovering and developing innovative medicines aimed at curing bacterial infections and enhancing the quality of life for individuals with chronic illnesses. The company focuses on creating antibiotics specifically designed to treat multi-drug resistant bacterial infections, offering advanced treatment options for patients both in hospitals and within the community. Cempra is currently advancing the development of its lead product, CEM-101, while simultaneously investing in new technologies to discover the next generation of antibiotics. Through this dual approach, Cempra aims to address the growing challenge of drug resistance in bacterial infections.
Serenex is a medical drug discovery and development company that focuses on oncology. The company develops Hsp90 product platform that provides a collection of small molecule Hsp90 inhibitors for cancer, inflammatory diseases, fungal infection resistance, viral diseases, and neurodegenerative diseases, such as Alzheimer's. It also develops SNX-1012, a product for oral mucositis in solid tumor patients. Serenex is a U.S.-based company that was founded in 2000 and it was acquired in 2008 by Pfizer.
Argolyn Bioscience is a biotechnology company that develops peptide drug candidates to treat serious diseases and disorders. The company’s products are based on amino acid analog substitution technology. The company's products include ABS201 for schizophrenia and ABS212 for pain.
Mixx is a user-driven social media platform that enables individuals to discover, share, and engage with content tailored to their interests and geographical location. Founded by Chris McGill, the platform combines elements of social networking with news sharing, allowing users to create a personalized experience similar to Digg, but focused on niche topics often overlooked by larger sites. Users can submit, edit, and vote on stories, photos, and videos, contributing to a dynamic community. Mixx also facilitates the creation of topic-based groups, further refining the news feed for participants. By partnering with niche publishers, Mixx aims to drive traffic between its platform and their content, providing a space for less mainstream stories to gain visibility. Since its inception, Mixx has continued to evolve, offering tools and applications that enhance user interaction and engagement within its social news ecosystem.
Viamet Pharmaceuticals specializes in the discovery and development of novel therapeutic agents targeting metalloenzymes through its proprietary Metallophile™ Technology. This innovative approach leverages the company’s expertise in bioinorganic chemistry to develop inhibitors that demonstrate significant therapeutic and commercial potential. Viamet focuses on creating best-in-class analogs of existing metalloenzyme inhibitors, which allows for the rapid and cost-effective generation of patentable small molecule compounds. The company’s therapeutic pipeline addresses critical health challenges, including invasive fungal infections, cancer, cardiovascular conditions, and orphan diseases, by targeting the body's ability to utilize essential metal ions such as zinc and iron.
Biolex Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutic proteins and monoclonal antibodies using its patented LEX System. This innovative technology genetically transforms the aquatic plant Lemna to facilitate the production of biologic product candidates that are challenging to manufacture. Biolex's primary product is designed to address the needs of patients afflicted with Hepatitis C, aiming to improve treatment outcomes through enhanced efficacy and potency of its therapeutic offerings.
FlatBurger, Inc. provides business infrastructure for supporting software developers working in hybrid software environments. It offers business infrastructure to complement the development tools employed in the Microsoft visual studio environment. The company focuses on serving the DotNetNuke community of software developers. FlatBurger, Inc. is based in Loudonville, New York with additional offices in northern Virginia and Troy.
Defywire, Inc. develops wireless connections between teachers, administrators, students, and parents. The company offers Mobile Guardian, a web-based administration console that allows centralized management of mobile users, applications, and school configuration information. Its Mobile Guardian provides access to critical information, reconnecting through cellular, wireless fidelity, satellite, LAN or WAN, or other communication protocols, as well as supports blackberry and various Windows mobile devices, XP desktops, notebooks, and tablet PC's. The company was founded in 2003 and is based in Reston, Virginia.
6th Sense Analytics provides software solutions for automated collection and analysis of software engineering process and product data. The company was founded in 2004 and is based in Morrisville, North Carolina. As of January 12, 2009, 6th Sense Analytics operates as a subsidiary of Rally Software Development Corp.
Clarabridge is a prominent Customer Experience Management platform that assists leading brands in enhancing their customer experience. The company employs advanced text analytics and enterprise survey tools to analyze various forms of customer feedback. By transforming this feedback into actionable insights, Clarabridge enables businesses to make informed decisions that improve customer satisfaction and engagement. Through its robust solutions, the company empowers organizations to understand their customers better and take decisive actions to elevate their overall experience.
Ziptronix, Inc. specializes in semiconductor integration technologies for the electronics industry. The company is known for its advanced chip stacking and three-dimensional integrated circuits, which enhance the density of signal paths through innovative bonding techniques. Its proprietary ZiBond and Direct Bond Interconnect technologies enable the bonding of silicon in a 3D configuration, optimizing performance and efficiency. Additionally, Ziptronix provides semiconductor substrates for microelectromechanical systems (MEMS) and radio-frequency (RF) devices, further expanding its offerings in the semiconductor market.
ALDAGEN is a biopharmaceutical company developing proprietary regenerative cell therapies that target significant unmet medical needs. We have four product candidates in clinical trials. Our most advanced product candidate is ALD-101. We are currently conducting a pivotal Phase 3 clinical trial of ALD-101 to evaluate its efficacy in improving umbilical cord blood, or cord blood, transplants used to treat inherited metabolic diseases in pediatric patients. We are also conducting or supporting Phase 1 or Phase 1/2 clinical trials of three other product candidates ALD--151 to improve cord blood transplants used for the treatment of leukemia; ALD-301 to treat critical limb ischemia; and ALD-201 to treat ischemic heart failure.
Jacket Micro Devices provides services and solutions for wireless modules. It offers a platform technology that reduces the size and cost of the radio frequency (RF) components used in wireless devices. The company also provides modules, design services, and substrates for integrated wireless products. In addition, it offers multi-layer organic (MLO) and low temperature laminated organic (LTLO) technologies for wireless system-in-package (SiP) designs. Jacket Micro Devices, Inc. was founded in 2004 and is based in Atlanta, Georgia.
nContact, Inc. is a medical device company specializing in the development of innovative solutions for the treatment of cardiac arrhythmias, particularly atrial fibrillation. Founded in 2005 and based in Morrisville, North Carolina, the company focuses on minimally invasive ablation procedures. Its flagship product, the Numeris Coagulation System with VisiTrax, utilizes a unique combination of suction, perfusion, and radiofrequency energy to create visible, nonconductive lesions on the epicardium of a beating heart. This system has received regulatory approval for use in the United States and holds CE Mark approval in Europe. nContact also offers a range of other devices designed to ensure consistent contact with cardiac tissue, facilitating effective lesion creation. The company has initiated clinical studies to further explore its technology's application in treating atrial fibrillation through both open and closed chest procedures. In 2011, nContact, formerly known as nContact Surgical, became a subsidiary of AtriCure, Inc.
Zenoss Inc. develops IT operations and application monitoring solutions, focusing on ensuring the reliability of IT services for large organizations. The company's flagship product, Zenoss Cloud, is a software-as-a-service platform that normalizes machine data to help prevent service disruptions in complex IT environments. Additionally, Zenoss offers VxRail HCI integration, allowing users to monitor entire VxRail deployments as cohesive units. Their solutions cater to various domains, including IT services, virtualization, and network monitoring, and are utilized by industries such as federal, financial, and technology sectors, as well as service providers. Zenoss has established strategic partnerships with notable companies like Accenture and AWS, enhancing its service offerings. Founded in 2005 and headquartered in Austin, Texas, with an office in Coventry, United Kingdom, Zenoss continues to lead in software-defined IT operations by leveraging machine learning to predict and mitigate potential outages, thus reducing downtime and associated costs.
Covega Corporation specializes in the development of optoelectronic components and subsystems, utilizing proprietary technologies in Indium Phosphide (InP) and Lithium Niobate (LiNbO3) to produce high-performance optical devices and modules. The company offers a range of products, including superluminescent diodes, semiconductor optical amplifiers, Fabry Perot lasers, gain chips, broad area lasers, and various types of modulators. Initially focused on the telecommunications, datacom, and CATV sectors, Covega has diversified its revenue streams and now derives over one-third of its income from the defense, medical, industrial, and instrumentation markets. By providing vertically integrated capabilities and foundry services, Covega meets the diverse needs of its clients across multiple industries with innovative and cost-effective solutions.
CallMiner, Inc. specializes in providing speech analytics solutions designed to enhance agent performance and improve contact center operations. The company offers a range of products, including the Eureka platform, which enables conversational analytics to uncover insights from interactions between agents and customers. It features tools such as myEureka for automated performance management, Eureka Live for real-time call monitoring, and Eureka Essentials for smaller contact centers. CallMiner's solutions are delivered through both Software-as-a-Service and on-premise installations, catering to various industries including financial services, utilities, manufacturing, and travel. Since its founding in 2002, CallMiner has established a significant presence in the market, with over 2 billion hours of conversations analyzed and a commitment to continuous improvement through customer feedback. The company also provides support services, training programs, and an online community for users. Headquartered in Waltham, Massachusetts, with additional offices in Fort Myers and the United Kingdom, CallMiner remains agile in adapting to the evolving needs of its clients.
Nitronex is a leading developer and manufacturer of gallium nitride-on-silicon (GaN-on-Si) RF power devices, specializing in high-performance semiconductors for various applications. Founded in 1999 by graduates of the wide bandgap program at North Carolina State University, the company is headquartered in Durham, North Carolina. Nitronex focuses on producing GaN-based RF power transistors that serve markets including wireless communications, broadband, and military applications. With a strong commitment to innovation, the company holds 21 patents and has an additional 17 patents pending, highlighting its role as a pioneer in the development of advanced semiconductor technology.